Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience.
OBJECTIVE
The aim of this study was to evaluate transsphenoidal surgery results in acromegalic patients which were performed not by a single surgeon but by different surgeons.


METHODS
The study included 30 (M/F: 13/17) patients whose follow-up data were available. Basal or nadir postglucose growth hormone levels of less than 2 ng/ml were accepted as cure criteria. Six of them underwent a further operation due to previous surgical failure.


RESULTS
Cure was achieved in 33% of patients while hypopituitarism was observed in 10% (3/30) of patients after the first operation. The cure rates were 63% and 15% in patients with microadenomas (n = 11) and macroadenomas (n = 19) respectively (p = 0.042). Only one of the patients (16%) who underwent a second operation achieved remission, while hypopituitarism was observed in five of them (83%). There was no significant difference in the cure rates between the first and second operation, but the risk of hypopituitarism was significantly higher in patients who underwent further surgery (p = 0.008).


CONCLUSIONS
The cure rate following surgery is significantly lower in acromegalic patients with macroadenomas than in patients with microadenomas. Cure probability decreases with a further operation, while complication risk increases significantly. Octreotide therapy, which could be used as an alternative therapy to the surgery, revealed high success rates in both microadenomas and macroadenomas. The low cure rates found in this study compared with published series could be attributed to the fact that operations were performed by inexperienced surgeons.
Erturk
Erdinc
E
Department of Endocrinology, Uludag University, School of Medicine, 16059, Bursa, Turkey. ererturk@uludag.edu.tr
Tuncel
Ercan
E
Kiyici
Sinem
S
Ersoy
Canan
C
Duran
Cevdet
C
Imamoglu
Sazi
S
D000172:Acromegaly / Q000188:drug therapy / Q000601:surgery*; D000236:Adenoma / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D002983:Clinical Competence; D005260:Female; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000601:surgery; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome
D019382:Human Growth Hormone; D015282:Octreotide